Accueil>>(Met¹⁸⁶)-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse)

(Met¹⁸⁶)-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse)

Catalog No.GA20255

This modified sequence of the gp100 epitope gp(209-217) (H-4106), in which a methionine replaced the natural threonine at position 2, bound to the HLA-A2 molecule with greater affinity than the unmodified peptide and was shown to have an increased ability to generate melanoma-reactive cytotoxic T lymphocytes (CTLs) in vitro when used for sensitization of peripheral blood mononuclear cells. This synthetic peptide hold promise for the development of novel cancer immunotherapies.

Products are for research use only. Not for human use. We do not sell to patients.

(Met¹⁸⁶)-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse) Chemical Structure

Cas No.: 181477-43-0

Taille Prix Stock Qté
1mg
143,00 $US
En stock
5mg
572,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

This modified sequence of the gp100 epitope gp(209-217), in which a methionine replaced the natural threonine at position 2, bound to the HLA-A2 molecule with greater affinity than the unmodified peptide and was shown to have an increased ability to ge

Avis

Review for (Met¹⁸⁶)-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse)

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (Met¹⁸⁶)-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.